Syra Health SYRA

OTC SYRA
$0.82 -0.07 (-7.87%)
At close: Oct 2, 2026 · 4:00 PM EDT
Key Stats
Market Cap12.32 Mn
Add ratio to table…

About

Syra Health Corp is an integrated healthcare solutions company serving government and commercial healthcare organizations with prevention-focused, accessible, and affordable solutions that improve health outcomes. The company delivers end-to-end capabilities across population health, behavioral and mental health, digital health, health education and training, and healthcare workforce development and staffing. It focuses on providing customized and comprehensive services to…

Read more ↓
Sectors: Healthcare Technology Sector rationale The company's primary business is delivering integrated healthcare solutions, including behavioral and mental health services, population health management, and the deployment of nurses and allied health professionals to hospitals. A secondary sector of Technology is justified because the company develops and sells its own proprietary software platforms, such as the Syrenity AI-driven mental health app, SyraBot, and CarePlus electronic medical records solutions. Industries: Healthcare Services Healthcare Services Primary Syra Health provides comprehensive healthcare services including population health management, behavioral and mental health services, and health education. These services are delivered to hospitals, state health departments, and managed care entities, fitting the description of outpatient and specialty care networks. Healthcare IT Healthcare IT Secondary The company develops and sells healthcare-specific software platforms, including CarePlus (an electronic medical records solution) and SyraBot (an AI-powered chatbot for patient engagement), which are purpose-built for healthcare administration and clinical workflows. Telehealth Telehealth Secondary The company operates the Syrenity application, which delivers remote mental health care, cognitive behavioral therapy, and virtual consultations with licensed mental health professionals. Classified using BQ-MICS CIK: 0001922335
Bull & bear

Investment Thesis

▲ Bull case
  • Syra Health is demonstrating a powerful inflection point in its business model through the successful integration of its AI-powered Syrenity platform with clinical provider networks like Nora Mental Health, creating a seamless digital-to-clinical care pathway that addresses critical gaps in mental health access, particularly in underserved and rural markets. The company's proprietary Guardrails framework ensures responsible AI deployment through pre-generative content controls and transparent private server infrastructure, differentiating Syrenity from generic AI mental health apps by maintaining clinical validity and HIPAA compliance while enabling scalable intervention. The platform's inclusion in an Indiana University clinical study showing measurable improvement in depression symptoms provides third-party validation that de-risks adoption by health plans and employers seeking evidence-based digital therapeutics. Furthermore, the shift in revenue mix toward high-margin Population Health solutions—which grew 46% year-over-year to $1.8 million in Q1 2026 and now represents 79% of total revenue—has driven gross margin expansion to 42.7%, up 11 percentage points from the prior year, indicating operating leverage is taking hold as lower-margin Healthcare Workforce solutions are strategically de-emphasized. This structural improvement in profitability is reinforced by a 27% year-over-year decline in salaries and benefits and an 81% plunge in R&D expenses, reflecting disciplined cost management without sacrificing core innovation, as evidenced by continued Syrenity development and partnership expansion. With Q1 2026 net income of $240,979 marking the first profitable quarter in the company's recent history and cash reserves growing to $2.9 million from $1.6 million at year-end 2025, Syra Health has achieved financial stability that reduces dilution risk and provides dry powder to scale the Syrenity-Nora model nationally, especially given Nora's existing footprint in 16 states and the clear pathway to replicate this B2B2C integration with other provider groups. The recognition via two 2026 Mira Awards—Industry's highest tech honors in Indiana—further validates Syra Health's technological differentiation and market readiness, signaling to potential enterprise clients that the company has moved beyond pilot stage into proven, scalable solutions with measurable clinical and economic outcomes.
▼ Bear case
  • Despite recent profitability and margin expansion, Syra Health remains highly vulnerable to the cyclical and politically sensitive nature of its government-facing revenue streams, as evidenced by the 9% year-over-year decline in FY2025 revenue to $7.2 million, which management explicitly attributed to the slowing or termination of federal government funding supporting state and county-level customers—a headwind that is not temporary but structural, given shifting fiscal priorities at the state level and potential future reductions in public health grants that have historically underpinned demand for its population health analytics and workforce solutions. While the company highlights growth in its Population Health segment, this growth is occurring off a depressed base and remains contingent on securing new contracts with financially strained local governments that may lack budgetary flexibility, especially as Medicaid reimbursement pressures and state-level fiscal constraints intensify post-pandemic. The apparent improvement in gross margins to 42.7% in Q1 2026 is partially inflated by a favorable shift in revenue mix away from lower-margin Healthcare Workforce solutions, which declined to $513,000 from $655,000 year-over-year, meaning the company is achieving higher margins not through operational efficiency in its core offerings but by strategically retreating from a business line that, while lower-margin, provided revenue diversification and customer cross-sell opportunities. Furthermore, the dramatic 81% reduction in R&D spending to $6,921 in Q1 2026 raises concerns about long-term innovation capacity, particularly as the company relies on the Syrenity platform—which, despite clinical validation from a single Indiana University study, lacks broad, peer-reviewed evidence of efficacy at scale or FDA clearance, leaving it vulnerable to competitive displacement by better-resourced digital health players with deeper clinical pipelines and regulatory advantages. The partnership with Nora Mental Health, while promising, remains geographically limited to Indiana with no disclosed financial terms, revenue share arrangements, or customer acquisition costs, making it difficult to assess whether this collaboration will generate meaningful, sustainable revenue or merely serve as a pilot with limited scalability; Nora’s own operations span 16 states, yet Syra Health has not disclosed any pipeline for expansion beyond the initial Indiana focus, suggesting execution risk in replicating this model nationally. Finally, although Syra Health ended Q1 2026 with $2.9 million in cash, its operating cash flow of $1.36 million was heavily driven by a $733,913 surge in deferred revenue—a liability representing unearned income that must be recognized in future periods and may not recur at the same level, creating a potential cliff in revenue recognition once these deferred obligations are fulfilled, especially if new contract bookings do not materialize at a comparable pace to sustain the current growth trajectory.

Customer Breakdown of Revenue (2022)

Product Or Service Breakdown of Revenue (2022)

Peer group

Peer Comparison

Companies in the Healthcare Services
View all peers
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 HCA HCA Healthcare, Inc. 92.33 Bn13.661.1849.72 Bn
2 NTRA Natera, Inc. 58.66 Bn-304.1921.670.08 Bn
3 DGX Quest Diagnostics Inc 25.51 Bn24.152.215.64 Bn
4 LH Labcorp Holdings Inc. 24.64 Bn24.831.725.86 Bn
5 GH Guardant Health, Inc. 23.35 Bn-51.2119.74-
6 THC Tenet Healthcare Corp 20.47 Bn9.470.9413.25 Bn
7 TEM Tempus AI, Inc. 13.40 Bn-54.109.36-
8 SYRA Syra Health Corp 0.01 Bn---